INDV Stock Forecast & Price Target

Indivior Pharmaceuticals has demonstrated a solid upward trend in its patient base for Sublocade, recording approximately 171,500 patients in 3Q25, reflecting an 8% increase from the previous year, alongside a growth in prescribers by 11%. Management has raised guidance for worldwide Sublocade sales to a range of $825 million to $845 million, suggesting a healthy annual growth rate of approximately 10% at the midpoint. The company's strategic focus on expense control, coupled with anticipated expansion in the long-acting injectable opioid use disorder market, strengthens the outlook for sustained long-term EBITDA growth and potential multiple expansion.

Indivior Pharmaceuticals is experiencing a significant reduction in its commercial footprint for Sublocade, having decreased support from approximately 40 countries to only four, which raises concerns about future revenue generation. The company's decision to discontinue commercial support for Opvee, a product that did not align with its primary focus, further highlights strategic challenges within its portfolio. Furthermore, with consensus projections indicating a revenue decline of around 6.5% in 2026 due to these portfolio simplification actions, there are underlying risks to financial stability and growth potential.